



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-1229)

TECH CENTER 1600/2900

RECEIVED

JUN 10 2002

In re Application of: Paszty et al.)

Serial No.: 09/928,175)

Filed: August 10, 2001)

For: Leucine-Rich Repeat-Containing)
G-Protein Coupled Receptor-8)
Molecules and Uses Thereof)

Before the Examiner:

Group Art Unit: 1645

TRANSMITTAL LETTER


Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
 - a) Information Disclosure Statement;
 - b) PTO Form 1449; and cited references
 - c) Return postcard
2. With respect to fees:
 - a) No fees are required
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage via Express Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on June 5, 2002.

Respectfully submitted,


Donald L. Zuhn, Ph.D.
Registration No. 35,303

Date: June 5, 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-1229)

PATENT

In re Application of: Paszty et al.)

Serial No.: 09/928,175)

Filed: August 10, 2001)

For: Leucine-Rich Repeat-Containing)
G-Protein Coupled Receptor-8)
Molecules and Uses Thereof)

Before the Examiner:

Group Art Unit: 1645

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT


This statement is filed under 37 C.F.R. §§ 1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, Applicants hereby authorize the Commissioner to charge the fee to Deposit Account No. 13-2490.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff


Donald L. Zuhn, Ph.D.
Reg. No. 48,710

Dated: June 5, 2002



Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application No.	09/928,175	
			Filing Date:	August 10, 2001	
			First Named Inventor	Paszy et al.	
			Group Art Unit	1645	
			Examiner Name		
Sheet	2	of	2	Attorney Docket No.	00-1229


OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
		DUFAU et al., "The Luteinizing Hormone Receptor", Annu. Rev. Physiol., 1998, 60:461-96.		
		HSU et al., "Characterization of Two LGR Genes Homologous to Gonadotropin and Thyrotropin Receptors with Extracellular Leucine-Rich Repeats and a G Protein-Coupled, Seven-Transmembrane Region", Mol. Endocrinol., 1998, 12:1830-45.		
		OSUGA et al., "Derivation of Functional Antagonists Using N-Terminal Extracellular Domain of Gonadotropin and Thyrotropin Receptors", 1997, Mol. Endocrinol. 11:1659-68.		
		MCDONALD et al., "Identification and Cloning of a Orphan G Protein-Coupled Receptor of the Glycoprotein Hormone Receptor Subfamily" Biochem. Biophys. Res. Commun. 1998, 247:266-70.		
		HSU et al., "The Three Subfamilies of Leucine-Rich Repeat-Containing G Protein-Coupled Receptors (LGR): Identification of LGR6 and LGR7 and the Signaling Mechanism for LGR7", 2000, Molecular Endocrinology 14(8): 1257-1271.		
		OVERBEEK et al., "A Transgenic Insertion Causing Cryptorchidism in Mice", 2001, Genesis the Journal of Genetics and Development, 30:26-35.		
		AGOULNIK and GORLOV, "Cloning Great-G Protein-Coupled Receptor Affecting Testicular Descent", American Journal of Human Genetics, 2001 69(4 Supplement):218.		
		Accession No. AC077689, Mus Musculus Strain C57BL6/J Chromosome 5 RP23-301H20		
		HSU et al. "Activation of Orphan Receptors by the Hormone Relaxin", 2002, Science vol 295 671-674		
		Accession No. AF346501, Mus Musculus G Protein Coupled Receptor Affecting Testicular descent (Great) mRNA, complete cds.		

RECEIVED
JUN 10 2002
TECH CENTER 1600/2900

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	09/928,175
Filing Date:	August 10, 2001
First Named Inventor	Paszty et al.
Group Art Unit	1645
Examiner Name	
Attorney Docket No.	00-1229

Sheet

1

of

2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		WO	99/48921	A	Board of Trustees of the Leland Stanford Junior Univeristy	09-30-99		
		WO	99/15660	A1	Merck & Co., Inc.	04-01-99		
		WO	99/15545	A1	Merck & Co., Inc.	04-1-99		
		WO	01/36471	A2	Arena Pharmaceuticals, Inc.			
		WO	01/68858	A2	Pharmacia & Upjohn Company	09-20-01		
		WO	01/88127	A2	Bayer Aktiengesellschaft	11-22-01		
		WO	02/14489	A2	Amgen, Inc.	02-21-02		
		EP	0950711	A2	Akzo Novel N.V.	10-20-99		

TECH CENTER 1600/2900

JUL 10 2002

RECEIVED

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.